Crossmark

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients

Crossref DOI link: https://doi.org/10.1186/s13023-018-0824-4

Published Online: 2018-05-22

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

van der Meijden, Jan C.

Kruijshaar, Michelle E.

Rizopoulos, Dimitris

van Doorn, Pieter A.

van der Beek, Nadine A. M. E.

van der Ploeg, Ans T.
License Information

Text and Data Mining valid from 2018-05-22
More Information

Article History

Received: 29 January 2018

Accepted: 9 May 2018

First Online: 22 May 2018

Ethics approval and consent to participate

: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. All patients and/or their parents provided informed consent. The medical ethical committee of the Erasmus MC approved the study protocol.

: AvdP has provided consultancy services to various industries, including Sanofi Genzyme who manufacture myozyme. JvdM, MK, DR, NvdB and PvD declare that they have no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.